LIXTE BIOTECHNOLOGY HOLDINGS, INC. Key Partnership Update

Understanding SEC filings can be tough, but staying informed about your investments is crucial. Let's cut through the jargon and clearly explain a recent material event from LIXTE BIOTECHNOLOGY HOLDINGS, INC. This guide breaks down the key details, so you can quickly grasp what's happening without getting lost in complex financial terms.

1. Event Description (What happened?)

LIXTE BIOTECHNOLOGY HOLDINGS, INC., a company developing new cancer treatments, recently restructured its partnership with Orbit Capital Inc. concerning Liora Technologies Europe Ltd. Liora is a crucial subsidiary that Lixte acquired to advance its drug development.

Lixte and Orbit consolidated and clarified several previous agreements into a single "Amended and Restated Share Exchange Agreement." This new agreement confirms Orbit Capital's 20% ownership of Liora. In exchange for this stake, Orbit relinquished its "special preferred shares" in Lixte – which typically offer specific dividend rights or liquidation preferences – and a "royalty agreement," granting a percentage of future sales from Liora's products. For these valuable assets, Orbit received 700,000 shares of Lixte's common stock.

2. Event Date/Timeline

Lixte filed this updated agreement with the SEC on March 6, 2026. However, the agreement is retroactively effective from November 21, 2025. This means Lixte and Orbit are formalizing their original intent, consolidating multiple steps that occurred between November and December 2025 into a single, clear legal document.

3. Rationale for the Event (Why did it happen?)

Lixte and Orbit entered into several agreements between November and December 2025 regarding Lixte's acquisition of Liora and their partnership terms. These separate agreements had become complex and did not fully reflect their final understanding of ownership and exchanges. The primary goal of this "Amended and Restated" agreement is to combine and clarify all terms, streamlining the legal paperwork.

Strategically, this move also aligns Orbit Capital's interests more directly with Lixte's long-term success. By exchanging preferred shares and a royalty agreement for Lixte common stock, Orbit now holds a direct stake in Lixte's overall performance and stock value, rather than just Liora's specific product sales or preferred dividends. This fosters a more unified partnership as Lixte continues to develop Liora's assets.

4. Impact Assessment (Who/What is affected?)

This development clearly defines Liora's ownership and strategic direction, a subsidiary with promising assets for Lixte's future drug development.

• Ownership & Control: Lixte, which initially acquired 100% of Liora, now holds an 80% majority stake, with Orbit Capital owning the remaining 20%. While Lixte retains ultimate control, this partnership structure implies shared decision-making and potentially shared resources or expertise from Orbit. This shift from full ownership to a majority partnership could influence how Liora's assets are funded and developed.
• Strategic Alignment: Orbit's decision to exchange preferred shares and a royalty stream for Lixte common stock signals confidence in Lixte's overall growth trajectory and potential stock appreciation. This creates a stronger, more aligned partnership.
• Liora's Potential: Liora Technologies Europe Ltd. remains critical to Lixte's pipeline. This clarified ownership structure enables both parties to advance Liora's development with defined roles and incentives.

Specific Parties Affected:

• Investors: The issuance of 700,000 new common shares affects investments in LIXTE stock by increasing the total number of shares outstanding, resulting in modest dilution of existing share value. The success of the Lixte-Orbit partnership in advancing Liora's drug candidates will also influence the long-term value of our investment.
• LIXTE: The company now holds a clear 80% ownership stake in Liora and partners with Orbit, whose 20% stake aligns its interests more closely with Lixte's stock performance. This could lead to shared funding, expertise, and risk for Liora's development.
• Orbit Capital: Orbit now owns 20% of Liora and 700,000 shares of Lixte's common stock, replacing its previous preferred shares and royalty agreement. This positions Orbit as a significant shareholder in Lixte and a key partner in Liora.
• Liora Technologies Europe Ltd: Its clearly defined ownership structure (80% Lixte, 20% Orbit) provides a stable foundation for its ongoing research and development efforts.

5. Financial Impact

• Share Issuance & Dilution: Lixte issued 700,000 new common shares to Orbit Capital. For context, if Lixte had approximately 30 million shares outstanding before this transaction, this issuance would represent roughly 2.3% dilution for existing shareholders. The company didn't provide the specific monetary value of these shares at Lixte's closing price on March 5, 2026 (the day before filing). However, this issuance implies the market value Lixte assigned to the assets Orbit relinquished.
• Implied Valuation: The value of the 700,000 Lixte shares issued to Orbit provides an implied valuation for the 20% stake in Liora and the assets Orbit gave up. This offers a useful data point for investors assessing Lixte's overall asset valuation.
• Shared Future Profits/Costs: Lixte will now share future profits (and potentially costs) from Liora with Orbit, reflecting its 80% ownership stake.

6. Key Takeaways for Investors

• Dilution Context: The issuance of 700,000 new common shares represents a modest percentage dilution (e.g., approximately 2.3% based on a hypothetical 30 million shares outstanding). Investors should always check Lixte's latest 10-Q or 10-K filing for the exact current share count to calculate the precise impact.
• Strategic Partnership, Not Drug News: Remember, this news concerns a corporate transaction, not a drug's success or failure in clinical trials, which often causes significant stock fluctuations in biotech companies. This filing clarifies how Lixte owns and partners on one of its key assets (Liora).
• Clarity & Alignment are Positive: While the process was complex, the "Amended and Restated" agreement brings clarity to the ownership and financial arrangements between Lixte and Orbit regarding Liora. This reduces legal uncertainty and aligns Orbit's incentives with Lixte's overall stock performance, which is generally positive for the company's long-term stability.
• Impact on Liora's Future: Lixte no longer owns 100% of Liora. This means Lixte will share future profits (and potentially costs) from Liora with Orbit. While Lixte's share of Liora's future success is now 80% instead of 100%, this also means shared risk and potentially access to Orbit's resources or expertise, which could accelerate Liora's development.
• What happens next? This filing primarily clarifies past transactions and sets the stage for Lixte and Orbit to move forward with their now-clarified ownership of Liora. There is no direct "next step" from this specific filing other than the new ownership structure being firmly in place. Lixte will continue its work with Liora under this new, clarified partnership, focusing on advancing Liora's pipeline assets. Investors should look for future updates on Liora's specific drug development progress.